

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: 16051256				
CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los boléanos utilizados**)				
Palabras clave utilizadas	{1-[1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, methods related.			
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA	CIP:): A61K31/4045; A61K9/20.			
	CPC (Opcional):			
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor*	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (con indicación, si procede, de las partes relevantes)	Categoría especiales de los documentos citados**
ESPACENET, USPTO	WO2011112662	15 de septiembre de 2011	No relevante para Método de Tratamiento	A
	Vanjoutte	2012	No relevante para Método de Tratamiento	A
	WO2010039939	8 de abril de 2010	No relevante para Método de Tratamiento	A
	US2014135350	15 de mayo de 2014	No relevante para Método de Tratamiento	A
** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.			“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.	

Literatura no patente *Se incluye entre otros, toda la referencia de la literatura no patente.	
Fecha del reporte de búsqueda:	31/10/2018

ESPACENET

Cited in	International search
	[X]➤ WO2011112662 (INCYTE CORP [US], et al) [X] 1,2,6-8,11,13,14,18,31,42-45 * page 50, line 1 - line 2; example 300 * * page 74, line 14 - line 26 * * page 82, line 14 - page 86, line 20; claims 1, 47 *;
	[A]➤ WO2010039939 (INCYTE CORP [US], et al) [A] 1-45 * claims 1, 8 *;
	[A]➤ US2009233903 (RODGERS JAMES D [US], et al) [A] 1-45 * paragraph [0219]; claim 1; table 1 *;
	[A] - MANISH J CHAUHAN ET AL, "A concise review on sustained drug delivery system and its opportunities", vol. 2, no. 2, ISSN 0974-4304, (20120301), pages 227 - 238, INTERNATIONAL JOURNAL OF PHARMTECH RESEARCH, SHPINX KNOWLEDGE HOUSE, IN, URL: http://www.ajptr.com/archive/volume-2/april-2012-issue-2/article-137.html , (20140102), XP002718280 [A] 1-45 * abstract *

ORBIT

Menu

Explorer

Patent family searches (FamPat)

Searches

Easy search

Advanced search

Semantic search

Assignee search

Number search

My session

Search history

Search	Result(s)	Query	Assistant	Source	Action
5	97248	(METHODS S RELATED)/BI/SA/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
4	1145	(SUSTAINED S RELEASE S DOSAGE S FORMS)/BI/SA/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
3	3709	(JAK1 AND INHIBITOR)/TX/BI/SA/KEYW/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
2	3709	(JAK1 AND INHIBITOR)/TX/BI/SA/KEYW/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
1	0	{1-{1-/TX/BI/SA/KEYW/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete

Easy search

Filter options

1 results for 3 AND 4 AND 5 - Collection: FAMPAT

Preview

Image

1st application year

After 2015 (0)

2011-2015 (1)

2006-2010 (0)

2001-2005 (0)

Before 2001 (0)

Assignee

INCYTE (1)

Litigations

#	Title	Publication number	1st app. date	Applicant/Assignee	Litigations
1	Sustained release dosage forms for a jak1 inhibitor	CA2920108	2014-08-06	INCYTE*	

This invention relates to sustained release dosage forms comprising {1-[1-3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl]acetoneitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.

FIG. 1A

PATBASE

PatBase

Username: SIC6@patbase.com

Subaccount: NELSON VELASCO

Menu Search History Session Folder Order Help Logoff

Search 3: 1 and 2

Results 1

Explore search

Edit and resend search

#	Search query	Results	Options
3	1 and 2	1	View Browse Hits Optimise more...
2	SUSTAINED RELEASE DOSAGE FORMS	96	View Browse Hits Optimise more...
1	STAC=(JAK1 INHIBITOR)	23	View Browse Hits Optimise more...

Information

Shortcuts

Command Reference

Bibliographic data

Textual data

PatBase

Username: SIC6@patbase.com

Subaccount: NELSON VELASCO

Menu Search History Session Folder Order Help Logoff

Search 3: "1 and 2" 1 of 1

Display format: Classic

Sorted by: Publication date asc

Print

Save/export

Snapshot

Visual explorer

Analytics

1) Family number: 58500091 (US2015065484A)

Similar Translate Full-text Status Citations

Title: [EN] SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR

Abstract: Source: US2015065484A [EN] This invention relates to sustained release dosage forms comprising {1-[1-3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl]acetoneitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.

Classifications: Classification Explorer

International (IPC) A61K A61K31/4045 A61K31/519 A61K47/12 A61K47/26 A61K47/38 A61K9/00 A61K9/20 A61K9/22 A61P1/04 A61P13/12 A61P17/00 A61P17/02 A61P17/04 A61P17/06 A61P19/00 A61P19/02 A61P19/08 A61P19/10 A61P21/04 A61P25/00 A61P25/28 A61P29/00 A61P31/10 A61P35/00 A61P35/02 A61P37/00 A61P37/06 A61P37/08 A61P43/00 A61P51/14 A61P51/50 A61P7/00 A61P7/06 A61P9/00 C07D47/04 C07D487/04 (Advanced/Invention); A61P35/00 A61P37/00 (Advanced/Non-invention); A61K (Subclass/Invention)

CPC: A61K31/519 A61K9/2018 A61K9/2013 A61K9/2059 A61K9/2054 A61K31/4045 A61K9/0053

US: 514/210 21 544/280

Family: Family Explorer

FIG. 1A

USPTO

uspto Patents Trademarks Fees and payment Help MyUSPTO

Public Patent Application Information Retrieval

Patent eBusiness Patent Application Information Retrieval

Global Dossier Order Certified Application As Filed Order Certified File Wrapper View Order List

14/453,129 SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR 20443-0258001

Select New Case Application Data Transaction History Image File Wrapper Patent Term Adjustments Continuity Data Fees Published Documents Address & Attorney/Agent Supplemental Content Assignments Display References

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click Start Download.

Available Documents

Mail Room Date	Document Code	Document Description	Document Category	Page Count	PDF
05-03-2017	ISSUE.NTF	Issue Notification	PROSECUTION	1	☐
04-20-2017	1449	List of References cited by applicant and considered by examiner	PRIOR ART	1	☐
04-20-2017	1449	List of References cited by applicant and considered by examiner	PRIOR ART	1	☐
04-14-2017	IFEE	Issue Fee Payment (PTO-85B)	PROSECUTION	1	☐
04-14-2017	WFEE	Fee Worksheet (SB06)	PROSECUTION	2	☐
04-14-2017	N417	EFS Acknowledgment Receipt	PROSECUTION	2	☐
04-14-2017	TRAN.LET	Transmittal Letter	PROSECUTION	2	☐
01-20-2017	NOA	Notice of Allowance and Fees Due (PTOL-85)	PROSECUTION	8	☐
01-20-2017	SRFW	Search information including classification, databases and other search related notes	PROSECUTION	1	☐
01-20-2017	SRNT	Examiner's search strategy and results	PROSECUTION	6	☐
01-20-2017	1449	List of References cited by applicant and considered by examiner	PRIOR ART	43	☐
01-20-2017	IIFW	Issue Information including classification, examiner, name, claim, renumbering, etc.	PROSECUTION	3	☐

EPOQUENET

Europäisches Patentamt
European Patent Office
Office européen des brevets

New connection on: : 31-10-2018 : 15:08:55 - Last disconnection on: : 31-10-2018 : 14:28:08

V 4.0.0.44358(LP,U,linux) (Rev:43856 2017-04-27 09:03:29 +0200#(D201802)) (RPM D201802)

Welcome to EPOQUE Rebuild under the Production Environment

[EPODOC: SS 1] ..fi

Select a database: ..FI EPODOC



Database: EPODOC

Records: 111.045.938

Terms: 1.468.768.108

Occurrences: 22.392.670.603

Last Update: 20181031

[EPODOC: SS 1] METHODS and RELATED

Results in EPODOC 161.259

[SS 2] SUSTAINED and RELEASE and DOSAGE and FORMS

Results in EPODOC 993

[SS 3] 1 and 2

Results in EPODOC 48

[SS 4] JAK1 AND INHIBITOR

Results in EPODOC 78

[SS 5] 3 and 4

Results in EPODOC 9

[SS 6] ..li ti ab pn




1/9 © EPODOC / EPO

TI - **SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR**

AB - This invention relates to **sustained release dosage forms** comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and **methods related** thereto.

FIG. 4(a)



2/9 © EPODOC / EPO

TI - **SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR.**

AB - This invention relates to **sustained release dosage forms** comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and **methods related** thereto.

PN - [MX2016001639](#) A 20161007

FIG. 4(a)





FIG. 4(b)




3/9 © EPODOC / EPO

TI - **SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR**

AB - This invention relates to **sustained release dosage forms** comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and **methods related** thereto.

FIG. 4(a)



4/9 © EPODOC / EPO

TI - **Sustained release dosage forms for a JAK1 inhibitor**

AB - This invention relates to **sustained release dosage forms** comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and **methods related** thereto.

PN - [CN105579032](#) A 20160511

FIG. 4(a)





FIG. 4(b)




5/9 © EPODOC / EPO

TI - **Sustained release dosage forms for a JAK1 inhibitor**

AB - This invention relates to **sustained release dosage forms** comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and **methods related** thereto.

FIG. 4(a)



6/9 © EPODOC / EPO

TI - **SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR**

AB - This invention relates to **sustained release dosage forms** comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and **methods related** thereto.

PN - [CA2920108](#) A1 20150212

FIG. 4(a)





FIG. 4(b)




7/9 © EPODOC / EPO

TI - **Sustained release dosage forms for a JAK1 inhibitor**

AB - This invention relates to **sustained release dosage forms** comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and **methods related** thereto.

FIG. 4(a)



8/9 © EPODOC / EPO

TI - (A1)

SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR

-(B2)

Sustained release dosage forms for a JAK1 inhibitor

AB - (A1 B2)

This invention relates to **sustained release dosage forms** comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and **methods related** thereto.

PN - [US2015065484](#) A1 20150305

FIG. 4(a)





FIG. 4(b)




9/9 © EPODOC / EPO

TI - **SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR**

AB - This invention relates to **sustained release dosage forms** comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and **methods related** thereto.

FIG. 4(a)



PN - [WO2015021153](#) A1 20150212

[SS 6]